Summit Therapeutics Inc. - 8-K Filing

Summit Therapeutics presented updated overall survival data from its HARMONi trial showing consistent results across Western and Asian patients, with a hazard ratio of 0.76 for global ITT population at June 2026 analysis.

SEC EDGAR · September 15, 2026, 12:45 UTC

Tickers: $SMMT

Read the full article at SEC EDGAR

More Regulatory news

LiveOne, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:45 UTC
Solana Co - 10-Q Filing SEC EDGAR · November 12, 2026, 13:42 UTC
Solana Co - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
DeFi Development Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 13:41 UTC
Stablecoin Development Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:40 UTC
BCP Investment Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:36 UTC
OneWater Marine Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Moleculin Biotech, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Investcorp Credit Management BDC, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:37 UTC
Presurance Holdings, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:35 UTC